Chen GM, Jain A, Gering DT, Satulovsky J, Datta S, Lai P, Karar J, Gonzalez VE, Alexander K, Chew A, Jadlowsky JK, Ruella M, Paruzzo L, Amses KR, Rech AJ, Stadtmauer EA, Frey NV, Hexner EO, Porter DL, Cohen AD, Gill SI, Garfall AL, Schuster SJ, Mo KC, Liang SI, Spasic M, Levine BL, Siegel DL, Ramírez-Fernández A, Cabanski CR, Yang E, Mackall CL, Bushman FD, Good Z, John Wherry E, June CH, Fraietta JA. Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer , Nat Biomed Eng: 2026
Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Day YA, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman A, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, de Souza VB, Patel H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli BT, Hung P, Williams E, Bartoszek R, Lavorando M, Mohan S, Gonzalez VE, Porazzi P, Bhoj VG, Apostolidis SA, Vogl DT, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M, Cohen AD, Fraietta JA. CD4(+) T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy , Nat Med: 2026
Patel H, Hubbeling H, Yu K, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya S. Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma , Blood Adv, 10: 2026,1395-1399
Yu KL, Ho M, Paruzzo L, Stella F, Patel H, Hasanali ZS, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S. Outcomes of relapse after teclistamab therapy in multiple myeloma , Blood Cancer J, 15: 2025,193
Shan X, Kuiper R, Ding C, Munshi PN, Stadtmauer EA, Susanibar-Adaniya SP. Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study , Haematologica, 110: 2025,2839-2843
Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol: 2025
Stalker M, Garfall A, Cohen A, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ. Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis , Eur J Haematol: 2025
Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, Landau HJ, Kumar SK, Vogl DT, Efebera YA, McCarthy PL, Vesole DH, Mendizabal A, Krishnan AY, Somlo G, Stadtmauer EA, Pasquini MC. Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702 , Leukemia: 2025
Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, Cohen AD, Garfall AL, Waxman AJ, Kapur S, Stadtmauer EA, Susanibar Adaniya S, Longworth S. Nontuberculous mycobacterial infections following teclistamab in multiple myeloma , Haematologica, 110: 2025,1436-1442
Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies , Nat Med: 2025
